• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation

Drugs Made In America Acquisition II Corp. (DMII)

Q2-CY2026

Q1-CY2026

Q4-CY2025

Q3-CY2025

Q2-CY2025

Q1-CY2025

Q4-CY2024

Q3-CY2024

Q2-CY2024

Q1-CY2024

Q4-CY2023

Q3-CY2023

Q2-CY2023

Q1-CY2023

Q4-CY2022

Q3-CY2022

Q2-CY2022

Q1-CY2022

Q4-CY2021

Q3-CY2021

Q2-CY2021

Q1-CY2021

Q4-CY2020

Q3-CY2020

Q2-CY2020

Q1-CY2020

Q4-CY2019

Q3-CY2019

Q2-CY2019

Q1-CY2019

Q4-CY2018

Q3-CY2018

Q2-CY2018

Q1-CY2018

Q4-CY2017

Q3-CY2017

Q2-CY2017

Q1-CY2017

Q4-CY2016

Q3-CY2016

Q2-CY2016

Q1-CY2016

Q4-CY2015

Q3-CY2015

Q2-CY2015

Q1-CY2015

Q4-CY2014

Q3-CY2014

Q2-CY2014

Balance Sheet Date

2025-Dec-31

2025-Sep-30

Fiscal Period

Q4-FY2025

Q3-FY2025

Total Revenue

QoQ%

YoY%

Cost Of Revenue

Gross Profit

Gross Margin

Operating Expenses

235,471$

155,513$

Operating Income

(235,472$)

(155,513$)

Operating Margin

Interest Income

4,824,445$

109,355$

Interest Expenses

Income Before Tax

4,330,608$

(46,158$)

(38,073$)

(59,327$)

Tax Expenses

Net Income

4,330,608$

(46,158$)

(38,073$)

(59,327$)

Profit Margin

TTM

Earnings to Minority

Earnings to Common Shareholders

4,330,608$

(46,158$)

(38,073$)

(59,327$)

QoQ%

9,482.14%

(21.24%)

35.83%

YoY%

Earnings Per Share, Basic

Earnings Per Share, Diluted

Unlevered FCF Per Share, Basic

Unlevered FCF Per Share, Diluted

Average Shares, Basic

Average Shares, Diluted

EBIT

4,330,608$

(46,158$)

(38,073$)

(59,327$)

EBITDA

4,330,608$

(46,158$)

(38,073$)

(59,327$)

Copy Table ✓